Search
Larimar Therapeutics Inc
LRMRAdd to Watchlist
3.820USD
-0.005-0.13%
Close 07-31 16:00（ET）Quotes delayed by 15 min
396.83MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Larimar Therapeutics Inc is 9.09, ranking 11 out of 385 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 26.00 and a low of 7.00.
Analyst Rating
Based on
11
analysts
Strong Buy
Current Rating
15.000
Target Price
+292.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Larimar Therapeutics Inc
LRMR
11
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Larimar Therapeutics Inc's price target?
Analysts forecast that Larimar Therapeutics Inc's price target is USD 18.00, with the highest forecast at USD 26.00 and the lowest forecast at USD 7.00.
How have Larimar Therapeutics IncLRMR's recent earnings per share performed?
The market expectation was USD -0.33, while Larimar Therapeutics IncLRMR's earnings per share (EPS) for the previous quarter was USD -0.73. EPS for the next quarter is expected at USD -0.38.
What is the analyst rating for Larimar Therapeutics Inc?
Based on the ratings of Larimar Therapeutics Inc's stock from 11 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.